GLP1R and metabolic dysfunction-associated steatotic liver disease: The aim of our study is to investigate whether of GLP1 receptor agonist have a pleiotropic metabolic effect and global impact to decrease cardiovascular risk and also reduce the risk of hepatic fibrosis in patients with MASLD.